37.47
Collegium Pharmaceutical Inc stock is traded at $37.47, with a volume of 646.72K.
It is up +1.19% in the last 24 hours and up +12.25% over the past month.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
See More
Previous Close:
$37.03
Open:
$37.27
24h Volume:
646.72K
Relative Volume:
1.37
Market Cap:
$1.22B
Revenue:
$796.33M
Net Income/Loss:
$74.95M
P/E Ratio:
18.34
EPS:
2.0427
Net Cash Flow:
$329.83M
1W Performance:
+4.14%
1M Performance:
+12.25%
6M Performance:
-18.91%
1Y Performance:
+23.46%
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Name
Collegium Pharmaceutical Inc
Sector
Phone
781-713-3699
Address
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
COLL
Collegium Pharmaceutical Inc
|
37.47 | 1.17B | 796.33M | 74.95M | 329.83M | 2.0427 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.89 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
9.72 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.29 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
75.42 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
547.25 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jan-10-25 | Upgrade | Needham | Hold → Buy |
| Jul-30-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-07-24 | Upgrade | Jefferies | Hold → Buy |
| May-10-24 | Downgrade | Needham | Buy → Hold |
| May-10-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-25-23 | Reiterated | Needham | Buy |
| May-02-23 | Resumed | Jefferies | Buy |
| Aug-08-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-15-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Aug-06-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Jul-14-20 | Initiated | BWS Financial | Sell |
| May-27-20 | Initiated | Guggenheim | Neutral |
| Feb-19-20 | Resumed | Jefferies | Buy |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-03-19 | Resumed | H.C. Wainwright | Buy |
| Apr-12-19 | Resumed | Janney | Buy |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Jan-16-19 | Reiterated | Needham | Buy |
| Mar-08-18 | Reiterated | H.C. Wainwright | Buy |
| Feb-07-18 | Reiterated | Needham | Buy |
| Dec-05-17 | Reiterated | Needham | Buy |
| Sep-11-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Reiterated | Needham | Buy |
| Sep-13-16 | Initiated | Gabelli & Co | Buy |
| Jun-01-15 | Initiated | Jefferies | Buy |
| Jun-01-15 | Initiated | Needham | Buy |
| Jun-01-15 | Initiated | Piper Jaffray | Overweight |
View All
Collegium Pharmaceutical Inc Stock (COLL) Latest News
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why - TradingView
Collegium (NASDAQ: COLL) details $655.6M AZSTARYS acquisition terms - Stock Titan
Collegium Pharmaceutical, Inc. Actuals & Estimates (NASDAQ:COLL) - TradingView
COLL Forecast — Price Target — Prediction for 2027 - TradingView
How (COLL) Movements Inform Risk Allocation Models - Stock Traders Daily
Collegium Pharmaceutical Inc (COLL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Collegium Pharmaceutical stock rises toward upper weekly range amid short-term recovery - Traders Union
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? - Yahoo Finance
Collegium Pharmaceutical Inc (COLL) Institutional Confidence - TradingKey
Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative? - simplywall.st
Collegium Pharmaceutical Inc (COLL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Collegium Pharmaceutical Inc (COLL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Collegium Pharmaceutical Inc (COLL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Collegium Pharmaceutical Inc (COLL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
COLL Stock Price, Quote & Chart - ChartMill
Collegium Pharmaceutical Inc - TradingKey
Collegium Pharmaceutical Inc (COLL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Collegium Pharmaceutical Inc (COLL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Trading Systems Reacting to (COLL) Volatility - Stock Traders Daily
Collegium Pharmaceutical Inc. Q1 2026 Earnings: EPS Surges Past Estimates on Strong Operational Execution - newsline.com
COLLEGIUM PHARMACEUTICAL (COLL) director exercises options, now holds 112,483 shares - Stock Titan
Collegium Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-Director SANTINI GINO - Moomoo
Collegium Pharmaceutical stock gains stall near resistance despite 4.17 percent weekly rise - Traders Union
Collegium Pharmaceutical grants 50,305 RSUs to 34 new hires as inducement under Nasdaq rules. - Pluang
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
2 Reasons to Sell COLL and 1 Stock to Buy Instead - Yahoo Finance
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness - Yahoo Finance
Collegium Pharmaceutical | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Collegium Pharmaceutical Gains Attention on Strong ADHD Portfolio and Q1 2026 BeatEPS Revision Trend - thelegaladvocate.com
This Insider Has Just Sold Shares In Collegium Pharmaceutical - 富途牛牛
Why Collegium Pharmaceutical Inc. (COLL) Stock Is Gaining Attention for Its ADHD Portfolio - Insider Monkey
Collegium to Participate in 2026 Jefferies Global Healthcare Conference - The Manila Times
Investors can stream Collegium's Jefferies healthcare fireside chat live - Stock Titan
Collegium Pharmaceutical Acquires ADHD Drug AZSTARYS® from Corium Therapeutics - geneonline.com
COLLCollegium Pharmaceutical Inc Stock Price and Quote - Finviz
Collegium Pharmaceutical (COLL) Holds Near Resistance After Slight DeclineOvernight Profile - dars.gov.et
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1 - TradingView
(COLL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story - simplywall.st
Collegium Pharmaceutical stock (US19459E1029): insider trade draws attention as Wall Street sees ups - AD HOC NEWS
Collegium (NASDAQ: COLL) director sells 20 shares, holds 83,952 - Stock Titan
Collegium Pharma Leans on ADHD to Drive Growth - TipRanks
Collegium pharmaceutical director sells $142k in shares By Investing.com - Investing.com Australia
Collegium pharmaceutical director sells $142k in shares - Investing.com India
Director Nancy Lurker awarded 8,741 RSUs at Collegium (COLL) - Stock Titan
Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL) - Stock Titan
Collegium (COLL) director sells shares, exercises options and receives RSU grant - Stock Titan
Director at Collegium (COLL) awarded 17,482 restricted stock units - Stock Titan
Director at Collegium (NASDAQ: COLL) receives 8,741 RSUs in equity award - Stock Titan
Director at Collegium (NASDAQ: COLL) awarded 8,741 RSUs in equity grant - Stock Titan
COLL (NASDAQ) Form 144 shows 4,127-share sale and 30-share resale notice - Stock Titan
Collegium Pharmaceutical Inc Stock (COLL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Collegium Pharmaceutical Inc Stock (COLL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Freund John Gordon | Director |
May 18 '26 |
Sale |
34.05 |
20 |
681 |
83,952 |
| Freund John Gordon | Director |
May 15 '26 |
Option Exercise |
16.49 |
8,700 |
143,463 |
88,099 |
| Freund John Gordon | Director |
May 15 '26 |
Sale |
34.54 |
4,127 |
142,547 |
83,972 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):